Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02844816 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT02844816: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02844816 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 172 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02844816, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions
- DRUG Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02844816
The ClinicalTrials.gov registry entry for NCT02844816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab is the first listed.
NCT02844816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02844816 about?
NCT02844816 is a clinical study titled "Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer". This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may...
What is the current status of trial NCT02844816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2017-03-13. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT02844816?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT02844816?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.